Hemophilia Inhibitor Genetics Study (HIGS)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1137 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-04-30

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Several non-genetic and genetic factors that could influence the risk of inhibitor development in hemophilia A have been discussed but not fully explored. The aim of the HIGS is to identify these genetic factors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hemophilia Inhibitor Previously Untreated Patient Study

NCT01652027

Hemophilia A

COMPLETED

Study Evaluating Inhibitor Specificity in Hemophilia A

NCT00151385

Hemophilia A

WITHDRAWN PHASE4

Emicizumab in Acquired Hemophilia A

NCT04188639

Hemophilia A, Acquired

COMPLETED PHASE2

Genetic Susceptibility to Factor VIII Inhibitors

NCT00344435

Hemophilia

COMPLETED

The Malmö International Brother Study (MIBS)

NCT00231751

Hemophilia A With Inhibitors

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of the HIGS is to determine host genetic factors, other than mutations within the factor VIII gene, that are associated with the development of inhibitors in severe hemophilia A and response to antigenic challenge by factor VIII. The study will involve three phases, enrolling family groups composed of brother pairs and their parents (Phase I) and siblings, a family group composed of a person with severe hemophilia and his parents (Phase II), and a group of unrelated people with severe hemophilia for the purpose of confirming associations identified in Phases I and II.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemophilia A With Inhibitor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

FAMILY_BASED

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Phase I, II, III

Phase I consists of a brother pair with hemophilia, one or both of whom has a history of inhibitors, and their parents; Phase II consists of a person with hemophilia and an inhibitor, and both his parents; Phase III consists of an unrelated group of people with hemophilia.

Blood draw

Intervention Type PROCEDURE

A single blood draw.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood draw

A single blood draw.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

N/A to this study.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Severe hemophilia A is defined as a baseline factor VIII level \<1%. A history of inhibitor is defined as ever having a Bethesda titer \> 1 BU.

Phase I.

Subjects with hemophilia are eligible for Phase I of the study if all of the following apply:

* An informed consent form, approved by the appropriate IRB/IEC, has been administered, signed, and dated.
* The subject has severe hemophilia A.
* The subject has a history of inhibitor or the subject has no history of inhibitor but has at least 100 exposure days to factor VIII products.
* Sufficient documentation exists to identify the subject's maximum lifetime Bethesda titer.
* The subject has a history of inhibitor and has one or more full brothers with severe hemophilia A, with or without an inhibitor, who are eligible for and have agreed to be in the study, and two parents who have agreed to be in the study or the subject does not have a history of inhibitor but has one or more full brothers with severe hemophilia A and a history of inhibitor who are eligible for and have agreed to be in the study, and two parents who have agreed to be in the study.

Subjects without hemophilia are eligible for Phase I of the study if all of the following apply:

* An informed consent form, approved by the appropriate IRB/IEC, has been administered, signed, and dated.
* The subject is the parent (mother or father) of, or the full sibling of, a subject with hemophilia who is eligible for Phase I of the study.

Phase II.

Subjects with hemophilia are eligible for Phase II of the study if all of the following apply:

* An informed consent form, approved by the appropriate IRB/IEC, has been administered, signed, and dated.
* The subject has severe hemophilia A.
* The subject has a history of inhibitor and two parents who have agreed to be in the study.
* Sufficient documentation exists to identify the subject's maximum lifetime Bethesda titer.

Subjects without hemophilia are eligible for Phase II of the study if all of the following apply:

* An informed consent form, approved by the appropriate IRB/IEC, has been administered, signed, and dated.
* The subject is the parent (mother or father) of a subject with hemophilia who is eligible for Phase II of the study.

Exclusion Criteria

Phase I.

Subjects (with or without hemophilia) are excluded from participation in Phase I if:

* The minimum family group, defined as a pair of full brothers with hemophilia, either concordant (both with) or discordant (one with, one without) for inhibitor, and both of their parents, is not enrolled.

Phase II.

Subjects are excluded from participation in Phase II if:

* The minimum family group, defined as a person with hemophilia and a history of inhibitor and his mother and father, is not enrolled.

Eligible Sex

ALL

Accepts Healthy Volunteers

No